Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights Sep. 12, 2007 By Jim Shrine Sepracor Inc. entered a potential $155 million deal with GlaxoSmithKline plc covering its insomnia product Lunesta in Europe and elsewhere, about six weeks after it filed for European approval of the drug. (BioWorld Today)Read More
RSS